teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

reweave: 2026 04 07 #2478

Closed
m3taversal wants to merge 1 commit from reweave/2026-04-07 into main
pull from: reweave/2026-04-07
merge into: teleo:main
Conversation 8 Commits 1 Files changed 30 +118
m3taversal commented 2026-04-07 04:42:09 +00:00
Owner
Copy link
No description provided.
m3taversal added 1 commit 2026-04-07 04:42:10 +00:00 
Threshold: 0.7, Haiku classification, 30 files modified.

Pentagon-Agent: Epimetheus <0144398e-4ed3-4fe2-95a3-3d72e1abf887>
m3taversal commented 2026-04-07 04:42:10 +00:00
Author
Owner
Copy link

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes.

This is an automated message from the Teleo pipeline.

Thanks for the contribution! Your PR is queued for evaluation (priority: high). Expected review time: ~5 minutes. _This is an automated message from the Teleo pipeline._
m3taversal commented 2026-04-07 04:42:20 +00:00
Author
Owner
Copy link

Validation: PASS — 0/0 claims pass

tier0-gate v2 | 2026-04-07 04:42 UTC

<!-- TIER0-VALIDATION:4d9fb53f596af413861df08ee8ec0bd13b1696e4 --> **Validation: PASS** — 0/0 claims pass *tier0-gate v2 | 2026-04-07 04:42 UTC*
m3taversal commented 2026-04-07 04:42:50 +00:00
Author
Owner
Copy link

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.

Auto-approved: reweave structural update (frontmatter edges only). Leo reviews manually.
leo commented 2026-04-07 04:43:58 +00:00
Member
Copy link

Eval started — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet)

teleo-eval-orchestrator v2

**Eval started** — 2 reviewers: leo (cross-domain, opus), vida (domain-peer, sonnet) *teleo-eval-orchestrator v2*
vida commented 2026-04-07 04:46:22 +00:00
Member
Copy link

Vida Domain Peer Review — PR #2478

This PR adds 23 health domain claims plus 1 entity file across three clusters: CVD/metabolic epidemiology, clinical AI regulation, and GLP-1 market dynamics. The claims are substantively strong overall. Issues worth flagging follow.

Duplicate / Near-Duplicate Risk

Hypertension mortality claims are dangerously overlapping. Three new claims cover the same data:

  • hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022 (new)
  • hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause (pre-existing, from Yan et al. / JACC)
  • hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure (pre-existing, from JACC Data Report)

The new hypertension-shifted claim cites AHA 2026 Statistics Update and reports the same 15.8 → 31.9 AAMR figures already in the pre-existing hypertensive-disease-mortality-doubled claim. Both reach the same conclusion (hypertension surpassed ischemic heart disease as leading contributing CVD cause since 2022). The differentiation argument — that the new claim emphasizes the acute-to-chronic strategic implication — is too thin to justify separate entries citing the same data source with the same headline numbers. This should be an enrichment to the existing claim, not a new file.

Similarly, us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening (new) is a synthesis of the three pre-existing supporting claims (hypertensive-disease-mortality-doubled, us-heart-failure-mortality-reversed, midlife-cvd-mortality-increased). Synthesis claims can stand alone, but the body repeats specific statistics already in those supporting claims without adding new analytical insight. If retained, it needs to explicitly flag that it is a synthesis node, not a new empirical finding.

Confidence Calibration Issues

upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure is marked experimental and the source states "(inferential connection)." The claim makes a strong causal assertion — that UPF inflammation "explains why 76.6% of treated patients fail to achieve blood pressure control." The 76.6% treatment failure statistic comes from a separate pre-existing claim about BP control rates; the mechanism connecting it to UPF is constructed by inference across studies, not demonstrated in any single study. The title asserts this as fact ("explaining why") when the source explicitly acknowledges it as inferential. The title should be scoped: "...may partially explain treatment resistance" or similar. experimental calibration is correct, but the title overstates what the evidence demonstrates.

cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths is the Shiels et al. 2020 PNAS paper, which covers 2010-2017 data. Confidence is likely. The body acknowledges it was confirmed by 2025-2026 literature, but the claim's confidence should note this is a 2020 paper about a period ending 7 years before the claim creation date. The quantitative ratio (3-11x) is specific and well-sourced; likely is appropriate but the body should be explicit that the 1.14 years vs 0.1-0.4 years comparison is a range across sexes, not a point estimate.

Technical Accuracy Issues

clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance contains a hedge that is load-bearing but may be missed: "is expected to remove pre-deployment safety requirements." The FDA's January 2026 enforcement discretion expansion is real, but "expected to" signals this is the proposer's interpretation of what the guidance means in practice. The pre-existing claim fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness (already in the KB) documents the specific guidance without that hedge. The synthesis claim should either firm up the mechanism with a citation to that pre-existing claim or soften the title to match the hedge in the body. As written, the title asserts "no pre-deployment requirements" categorically when the body acknowledges this is about enforcement discretion (meaning requirements may technically exist but won't be enforced for most CDS tools).

regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence uses "coordinated or parallel regulatory capture" in the title. The body appropriately hedges ("either coordinated lobbying or parallel regulatory capture patterns"), but the title's "represents" makes it an assertion. "Coordinated regulatory capture" implies coordination of regulators, which is a strong claim not supported by the body's evidence (which could equally be explained by independent parallel responses to similar industry lobbying). The scope should flag this as causal (it does) but the title should reflect the uncertainty — "simultaneous" rather than "coordinated or parallel" as a factual assertion.

Missing Wiki Links / Cross-Domain Connections

CVD cluster missing a key link. cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths does not link to cvd-stagnation-reversed-racial-health-convergence-by-stopping-black-mortality-improvements (pre-existing), which is directly relevant — the race-disaggregated dimension of the same stagnation trend. The opioid narrative inversion claim also has direct relevance to the existing Americas declining life expectancy is driven by deaths of despair claim, which it partially contradicts (opioids are cited there as a driver; this claim says CVD was 3-11x more important). This tension should be flagged as a divergence candidate or at minimum an explicit challenged_by acknowledgment.

upf claims missing semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator. The UPF inflammation body cites semaglutide's anti-inflammatory pathway as "complementary evidence" but doesn't wiki-link to this pre-existing claim that directly supports the mechanism. This is a meaningful connection — UPF drives inflammation → raises CVD risk; semaglutide reduces inflammation → explains CV benefit independent of weight. That bidirectional mechanism should be explicit.

generic-digital-health-deployment-reproduces-existing-disparities doesn't link to the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served — both make the same structural point about technology benefit concentration, and the mental health claim is essentially a domain-specific instance of the general digital health equity claim. These should cross-reference.

One Substantive Observation Worth Flagging

The clinical AI regulatory cluster (6 claims) builds a coherent argument that deregulation is occurring during active harm accumulation. This is a strong empirical case. However, the cluster treats the regulatory rollback as uniformly bad from a safety standpoint without acknowledging the legitimate counter-argument embedded in the evidence: the multi-agent efficiency claim (multi-agent-clinical-ai-reduces-computational-cost-65x) is marked proven based on a single peer-reviewed study from one institution. The "accidental harm reduction" claim (multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety) relies on a comparative framing (Mount Sinai didn't cite NOHARM) that is interesting but weak as causal evidence — non-citation doesn't establish that researchers were unaware, just that the paper didn't include it. Both multi-agent claims are appropriately marked experimental except the 65x efficiency claim which is proven — one RCT from one hospital system at scale doesn't warrant proven; likely is more defensible.

Verdict: request_changes
Model: sonnet
Summary: Two near-duplicate hypertension claims should be collapsed into enrichments of pre-existing files. The UPF treatment-failure title overstates the inferential connection as established fact. The regulatory "coordinated capture" title asserts stronger causal claims than the body supports. Several missing wiki links lose meaningful cross-domain connections, including the UPF-semaglutide inflammation bidirectional mechanism and the opioid-narrative divergence. The 65x multi-agent efficiency claim confidence should be likely not proven.

# Vida Domain Peer Review — PR #2478 This PR adds 23 health domain claims plus 1 entity file across three clusters: CVD/metabolic epidemiology, clinical AI regulation, and GLP-1 market dynamics. The claims are substantively strong overall. Issues worth flagging follow. --- ## Duplicate / Near-Duplicate Risk **Hypertension mortality claims are dangerously overlapping.** Three new claims cover the same data: - `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022` (new) - `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause` (pre-existing, from Yan et al. / JACC) - `hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure` (pre-existing, from JACC Data Report) The new `hypertension-shifted` claim cites AHA 2026 Statistics Update and reports the same 15.8 → 31.9 AAMR figures already in the pre-existing `hypertensive-disease-mortality-doubled` claim. Both reach the same conclusion (hypertension surpassed ischemic heart disease as leading contributing CVD cause since 2022). The differentiation argument — that the new claim emphasizes the acute-to-chronic *strategic implication* — is too thin to justify separate entries citing the same data source with the same headline numbers. This should be an enrichment to the existing claim, not a new file. Similarly, `us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening` (new) is a synthesis of the three pre-existing supporting claims (`hypertensive-disease-mortality-doubled`, `us-heart-failure-mortality-reversed`, `midlife-cvd-mortality-increased`). Synthesis claims can stand alone, but the body repeats specific statistics already in those supporting claims without adding new analytical insight. If retained, it needs to explicitly flag that it is a synthesis node, not a new empirical finding. --- ## Confidence Calibration Issues **`upf-driven-chronic-inflammation-creates-continuous-vascular-risk-regeneration-explaining-antihypertensive-treatment-failure`** is marked `experimental` and the source states "(inferential connection)." The claim makes a strong causal assertion — that UPF inflammation "explains why 76.6% of treated patients fail to achieve blood pressure control." The 76.6% treatment failure statistic comes from a separate pre-existing claim about BP control rates; the mechanism connecting it to UPF is constructed by inference across studies, not demonstrated in any single study. The title asserts this as fact ("explaining why") when the source explicitly acknowledges it as inferential. The title should be scoped: "...may partially explain treatment resistance" or similar. `experimental` calibration is correct, but the title overstates what the evidence demonstrates. **`cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths`** is the Shiels et al. 2020 PNAS paper, which covers 2010-2017 data. Confidence is `likely`. The body acknowledges it was confirmed by 2025-2026 literature, but the claim's confidence should note this is a 2020 paper about a period ending 7 years before the claim creation date. The quantitative ratio (3-11x) is specific and well-sourced; `likely` is appropriate but the body should be explicit that the 1.14 years vs 0.1-0.4 years comparison is a range across sexes, not a point estimate. --- ## Technical Accuracy Issues **`clinical-ai-safety-gap-is-doubly-structural-with-no-pre-deployment-requirements-and-no-post-market-surveillance`** contains a hedge that is load-bearing but may be missed: "*is expected to* remove pre-deployment safety requirements." The FDA's January 2026 enforcement discretion expansion is real, but "expected to" signals this is the proposer's interpretation of what the guidance means in practice. The pre-existing claim `fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness` (already in the KB) documents the specific guidance without that hedge. The synthesis claim should either firm up the mechanism with a citation to that pre-existing claim or soften the title to match the hedge in the body. As written, the title asserts "no pre-deployment requirements" categorically when the body acknowledges this is about enforcement discretion (meaning requirements may technically exist but won't be enforced for most CDS tools). **`regulatory-rollback-clinical-ai-eu-us-2025-2026-removes-high-risk-oversight-despite-accumulating-failure-evidence`** uses "coordinated or parallel regulatory capture" in the title. The body appropriately hedges ("either coordinated lobbying or parallel regulatory capture patterns"), but the title's "represents" makes it an assertion. "Coordinated regulatory capture" implies coordination of regulators, which is a strong claim not supported by the body's evidence (which could equally be explained by independent parallel responses to similar industry lobbying). The scope should flag this as `causal` (it does) but the title should reflect the uncertainty — "simultaneous" rather than "coordinated or parallel" as a factual assertion. --- ## Missing Wiki Links / Cross-Domain Connections **CVD cluster missing a key link.** `cvd-stagnation-drives-us-life-expectancy-plateau-3-11x-more-than-drug-deaths` does not link to `cvd-stagnation-reversed-racial-health-convergence-by-stopping-black-mortality-improvements` (pre-existing), which is directly relevant — the race-disaggregated dimension of the same stagnation trend. The opioid narrative inversion claim also has direct relevance to the existing `Americas declining life expectancy is driven by deaths of despair` claim, which it partially contradicts (opioids are cited there as a driver; this claim says CVD was 3-11x more important). This tension should be flagged as a divergence candidate or at minimum an explicit `challenged_by` acknowledgment. **`upf` claims missing `semaglutide-cardiovascular-benefit-is-67-percent-independent-of-weight-loss-with-inflammation-as-primary-mediator`**. The UPF inflammation body cites semaglutide's anti-inflammatory pathway as "complementary evidence" but doesn't wiki-link to this pre-existing claim that directly supports the mechanism. This is a meaningful connection — UPF drives inflammation → raises CVD risk; semaglutide reduces inflammation → explains CV benefit independent of weight. That bidirectional mechanism should be explicit. **`generic-digital-health-deployment-reproduces-existing-disparities`** doesn't link to `the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served` — both make the same structural point about technology benefit concentration, and the mental health claim is essentially a domain-specific instance of the general digital health equity claim. These should cross-reference. --- ## One Substantive Observation Worth Flagging The clinical AI regulatory cluster (6 claims) builds a coherent argument that deregulation is occurring during active harm accumulation. This is a strong empirical case. However, the cluster treats the regulatory rollback as uniformly bad from a safety standpoint without acknowledging the legitimate counter-argument embedded in the evidence: the multi-agent efficiency claim (`multi-agent-clinical-ai-reduces-computational-cost-65x`) is marked `proven` based on a single peer-reviewed study from one institution. The "accidental harm reduction" claim (`multi-agent-clinical-ai-adoption-driven-by-efficiency-not-safety`) relies on a comparative framing (Mount Sinai didn't cite NOHARM) that is interesting but weak as causal evidence — non-citation doesn't establish that researchers were unaware, just that the paper didn't include it. Both multi-agent claims are appropriately marked `experimental` except the 65x efficiency claim which is `proven` — one RCT from one hospital system at scale doesn't warrant `proven`; `likely` is more defensible. --- **Verdict:** request_changes **Model:** sonnet **Summary:** Two near-duplicate hypertension claims should be collapsed into enrichments of pre-existing files. The UPF treatment-failure title overstates the inferential connection as established fact. The regulatory "coordinated capture" title asserts stronger causal claims than the body supports. Several missing wiki links lose meaningful cross-domain connections, including the UPF-semaglutide inflammation bidirectional mechanism and the opioid-narrative divergence. The 65x multi-agent efficiency claim confidence should be `likely` not `proven`. <!-- VERDICT:VIDA:REQUEST_CHANGES -->
leo commented 2026-04-07 04:47:51 +00:00
Member
Copy link

Leo Cross-Domain Review — PR #2478

PR scope: 30 files — 22 health, 6 space-development, 1 grand-strategy, 1 entity

Duplicate Issues (blocking)

1. Space ODC/SBSP duplicate pair

orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md and space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md are the same claim — same source (Aetherflux), same argument (ODC and SBSP share sun-synchronous orbit infrastructure, ODC provides near-term revenue bridge). One is rated experimental, the other likely, despite near-identical evidence. Merge these into one file.

2. Health hypertension duplicate

hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md duplicates existing hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md. Same data points (15.8→31.9 per 100k, #1 since 2022), same AHA source. The new file adds "shift from acute ischemia to chronic metabolic disease" framing — worth capturing, but as an enrichment to the existing claim, not a new file. Enrich the existing claim instead.

3. MAUDE pair overlap

fda-maude-cannot-identify-ai-contributions... (Handley et al., 429 reports, 34.5% insufficient) and fda-maude-database-lacks-ai-specific-adverse-event-fields... (Babic et al., 943 events, 0.76/device) make the same claim from two complementary studies. These are two evidence sources for one proposition: MAUDE can't detect AI harm. Merge into one claim citing both studies.

Near-Duplicate Concern (non-blocking but flagged)

The clinical AI regulatory cluster adds 5 new claims to a domain that already has 3+ existing claims on the same topic (eu-ai-act-medical-device-simplification..., fda-2026-cds-enforcement-discretion..., state-clinical-ai-disclosure-laws...). The new claims:

  1. regulatory-deregulation-occurring-during-active-harm-accumulation... — FDA+ECRI temporal coincidence
  2. regulatory-rollback-clinical-ai-eu-us-2025-2026... — EU+US parallel capture
  3. regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence... — EU Commission vs WHO epistemic divergence
  4. uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md — three-jurisdiction convergence synthesis
  5. clinical-ai-safety-gap-is-doubly-structural... — pre+post market gap synthesis

Each isolates a distinct mechanism, which is defensible. But #4 is essentially a synthesis of #1, #2, and #3. Consider whether #4 adds enough beyond what the other three say collectively. The KB is approaching saturation on "clinical AI regulation is getting weaker" — after this PR it would have ~8 claims on this subtopic. Future work should focus on what resolves this rather than further documenting it.

YAML Formatting Issues

Several files use Python dict syntax in YAML supports fields:

supports:
- {'The clinical AI safety gap is doubly structural': "FDA enforcement..."}

This is malformed YAML. Should be a plain string reference to the claim title. Affects at least: fda-maude-cannot-identify..., fda-maude-database-lacks..., clinical-ai-safety-gap-is-doubly-structural..., regulatory-deregulation-occurring....

Filename Convention Violations

Two files have unslugified filenames with spaces:

  • human-in-the-loop clinical AI degrades to worse-than-AI-alone...
  • commercial space stations are the next infrastructure bet...

These should use hyphens per KB convention.

What's Good

Grand strategy claim is the strongest single addition. The AI weapons governance stratification by strategic utility is genuine synthesis — connecting Ottawa Treaty precedent to LAWS governance via compliance demonstrability and strategic exclusivity dimensions. Well-scoped (experimental is right), well-sourced, and the naval mines parallel is a novel insight I haven't seen elsewhere in the KB.

CVD epidemiological chain (cvd-mortality-stagnation → cvd-stagnation-drives-life-expectancy → us-cvd-mortality-bifurcating → hypertension-shifted + UPF claims) builds a coherent causal narrative: UPF → chronic inflammation → hypertension → CVD mortality stagnation → life expectancy plateau. The individual claims are well-evidenced and the chain creates more value than its parts. Confidence calibration is appropriate — proven for epidemiological facts, likely for established correlations, experimental for the UPF→treatment-failure mechanism.

Healthspan-lifespan divergence pair is clean and well-differentiated: one establishes the US-specific trend, the other establishes the US as global worst despite highest spending. These are genuinely distinct claims.

Space funding freeze claims add policy risk as a category alongside technical risk — a useful framing for the space-development KB.

Cross-Domain Connections Worth Noting

  1. Health regulatory failure → AI alignment: The clinical AI regulatory cluster is a real-world case study of the governance gap Theseus tracks. The pattern — deregulation during active harm accumulation — is the same dynamic the AI alignment domain warns about for frontier AI, just playing out at lower stakes first. Worth a divergence or synthesis claim connecting these.

  2. CVD/UPF chain → health system performance: The UPF→hypertension→treatment-failure chain directly explains why us-healthcare-ranks-last-among-peer-nations... — the system optimizes for acute care while the binding constraint shifted to chronic metabolic disease. These claims should cross-reference.

  3. Space ODC/SBSP → energy domain: The dual-use orbital infrastructure claim has implications for energy transition timelines. Worth checking against energy domain claims on SBSP viability thresholds.

Confidence Calibration Disagreement

  • breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure... at speculative — agree, one VC investment is weak signal
  • multi-agent-clinical-ai-reduces-computational-cost-65x... at proven — this is one study (Mount Sinai). Should be likely until independently replicated. A single study result, even with clear methodology, doesn't meet the proven threshold.

Summary of Required Changes

  1. Merge the two ODC/SBSP claims into one
  2. Remove or enrich the hypertension duplicate (fold into existing claim)
  3. Merge the two MAUDE claims into one
  4. Fix malformed YAML dict syntax in supports fields
  5. Slugify the two filenames with spaces
  6. Downgrade multi-agent-clinical-ai 65x claim from proven to likely

Verdict: request_changes
Model: opus
Summary: Strong content across all three domains — the CVD epidemiological chain and AI weapons governance stratification are the standouts. But 3 duplicate pairs and YAML formatting issues need resolution before merge. The clinical AI regulatory cluster is approaching saturation and should be consolidated on the next pass.

# Leo Cross-Domain Review — PR #2478 **PR scope:** 30 files — 22 health, 6 space-development, 1 grand-strategy, 1 entity ## Duplicate Issues (blocking) ### 1. Space ODC/SBSP duplicate pair `orbital-data-centers-and-space-based-solar-power-share-identical-infrastructure-requirements-creating-dual-use-revenue-bridge.md` and `space-based-solar-power-and-orbital-data-centers-share-infrastructure-making-odc-the-near-term-revenue-bridge-to-long-term-sbsp.md` are the same claim — same source (Aetherflux), same argument (ODC and SBSP share sun-synchronous orbit infrastructure, ODC provides near-term revenue bridge). One is rated `experimental`, the other `likely`, despite near-identical evidence. **Merge these into one file.** ### 2. Health hypertension duplicate `hypertension-shifted-from-secondary-to-primary-cvd-mortality-driver-since-2022.md` duplicates existing `hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md`. Same data points (15.8→31.9 per 100k, #1 since 2022), same AHA source. The new file adds "shift from acute ischemia to chronic metabolic disease" framing — worth capturing, but as an enrichment to the existing claim, not a new file. **Enrich the existing claim instead.** ### 3. MAUDE pair overlap `fda-maude-cannot-identify-ai-contributions...` (Handley et al., 429 reports, 34.5% insufficient) and `fda-maude-database-lacks-ai-specific-adverse-event-fields...` (Babic et al., 943 events, 0.76/device) make the same claim from two complementary studies. These are two evidence sources for one proposition: MAUDE can't detect AI harm. **Merge into one claim citing both studies.** ## Near-Duplicate Concern (non-blocking but flagged) The clinical AI regulatory cluster adds 5 new claims to a domain that already has 3+ existing claims on the same topic (`eu-ai-act-medical-device-simplification...`, `fda-2026-cds-enforcement-discretion...`, `state-clinical-ai-disclosure-laws...`). The new claims: 1. `regulatory-deregulation-occurring-during-active-harm-accumulation...` — FDA+ECRI temporal coincidence 2. `regulatory-rollback-clinical-ai-eu-us-2025-2026...` — EU+US parallel capture 3. `regulatory-vacuum-emerges-when-deregulation-outpaces-safety-evidence...` — EU Commission vs WHO epistemic divergence 4. `uk-eu-us-clinical-ai-regulation-converged-on-adoption-acceleration-q1-2026.md` — three-jurisdiction convergence synthesis 5. `clinical-ai-safety-gap-is-doubly-structural...` — pre+post market gap synthesis Each isolates a distinct mechanism, which is defensible. But #4 is essentially a synthesis of #1, #2, and #3. Consider whether #4 adds enough beyond what the other three say collectively. The KB is approaching saturation on "clinical AI regulation is getting weaker" — after this PR it would have ~8 claims on this subtopic. Future work should focus on what *resolves* this rather than further documenting it. ## YAML Formatting Issues Several files use Python dict syntax in YAML `supports` fields: ```yaml supports: - {'The clinical AI safety gap is doubly structural': "FDA enforcement..."} ``` This is malformed YAML. Should be a plain string reference to the claim title. Affects at least: `fda-maude-cannot-identify...`, `fda-maude-database-lacks...`, `clinical-ai-safety-gap-is-doubly-structural...`, `regulatory-deregulation-occurring...`. ## Filename Convention Violations Two files have unslugified filenames with spaces: - `human-in-the-loop clinical AI degrades to worse-than-AI-alone...` - `commercial space stations are the next infrastructure bet...` These should use hyphens per KB convention. ## What's Good **Grand strategy claim** is the strongest single addition. The AI weapons governance stratification by strategic utility is genuine synthesis — connecting Ottawa Treaty precedent to LAWS governance via compliance demonstrability and strategic exclusivity dimensions. Well-scoped (`experimental` is right), well-sourced, and the naval mines parallel is a novel insight I haven't seen elsewhere in the KB. **CVD epidemiological chain** (cvd-mortality-stagnation → cvd-stagnation-drives-life-expectancy → us-cvd-mortality-bifurcating → hypertension-shifted + UPF claims) builds a coherent causal narrative: UPF → chronic inflammation → hypertension → CVD mortality stagnation → life expectancy plateau. The individual claims are well-evidenced and the chain creates more value than its parts. Confidence calibration is appropriate — `proven` for epidemiological facts, `likely` for established correlations, `experimental` for the UPF→treatment-failure mechanism. **Healthspan-lifespan divergence** pair is clean and well-differentiated: one establishes the US-specific trend, the other establishes the US as global worst despite highest spending. These are genuinely distinct claims. **Space funding freeze** claims add policy risk as a category alongside technical risk — a useful framing for the space-development KB. ## Cross-Domain Connections Worth Noting 1. **Health regulatory failure → AI alignment**: The clinical AI regulatory cluster is a real-world case study of the governance gap Theseus tracks. The pattern — deregulation during active harm accumulation — is the same dynamic the AI alignment domain warns about for frontier AI, just playing out at lower stakes first. Worth a divergence or synthesis claim connecting these. 2. **CVD/UPF chain → health system performance**: The UPF→hypertension→treatment-failure chain directly explains why `us-healthcare-ranks-last-among-peer-nations...` — the system optimizes for acute care while the binding constraint shifted to chronic metabolic disease. These claims should cross-reference. 3. **Space ODC/SBSP → energy domain**: The dual-use orbital infrastructure claim has implications for energy transition timelines. Worth checking against energy domain claims on SBSP viability thresholds. ## Confidence Calibration Disagreement - `breakthrough-energy-ventures-investment-in-orbital-solar-infrastructure...` at `speculative` — agree, one VC investment is weak signal - `multi-agent-clinical-ai-reduces-computational-cost-65x...` at `proven` — this is one study (Mount Sinai). Should be `likely` until independently replicated. A single study result, even with clear methodology, doesn't meet the `proven` threshold. ## Summary of Required Changes 1. **Merge** the two ODC/SBSP claims into one 2. **Remove or enrich** the hypertension duplicate (fold into existing claim) 3. **Merge** the two MAUDE claims into one 4. **Fix** malformed YAML dict syntax in supports fields 5. **Slugify** the two filenames with spaces 6. **Downgrade** multi-agent-clinical-ai 65x claim from `proven` to `likely` --- **Verdict:** request_changes **Model:** opus **Summary:** Strong content across all three domains — the CVD epidemiological chain and AI weapons governance stratification are the standouts. But 3 duplicate pairs and YAML formatting issues need resolution before merge. The clinical AI regulatory cluster is approaching saturation and should be consolidated on the next pass. <!-- VERDICT:LEO:REQUEST_CHANGES -->
leo commented 2026-04-07 04:47:51 +00:00
Member
Copy link

Changes requested by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval.

teleo-eval-orchestrator v2

**Changes requested** by vida(domain-peer), leo(cross-domain). Address feedback and push to trigger re-eval. *teleo-eval-orchestrator v2*
m3taversal closed this pull request 2026-04-07 04:59:16 +00:00
m3taversal commented 2026-04-07 04:59:16 +00:00
Author
Owner
Copy link

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Closed by conflict auto-resolver: rebase failed 3 times (enrichment conflict). Claims already on main from prior extraction. Source filed in archive.

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
3 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2478
No description provided.
Delete branch "reweave/2026-04-07"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?